Biotechnology
Commented by Armin Schulz on August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
Read
Commented by Juliane Zielonka on August 9th, 2024 | 06:30 CEST
Cardiol Therapeutics, Novo Nordisk, Bayer - Pharma stocks in focus
The healthcare sector promises further blockbusters for investors. Cardiol Therapeutics impresses with its promising Phase II study of CardiolRx™ for the treatment of the heart disease pericarditis. The growing market for pericarditis treatments offers the Company great potential, which has also been positively noted by analysts. The Danish company Novo Nordisk is experiencing impressive growth thanks to its GLP-1-based diabetes and obesity drugs. The active ingredient is causing a stir in the celebrity scene as an off-label weight loss injection, further boosting the Company's sales figures. Bayer AG is facing up to its challenges. Despite slight revenue growth in the second quarter of 2024, profits declined. Nevertheless, CEO Bill Anderson believes the Company is on the right track, particularly thanks to progress in the pharmaceutical pipeline. We have three companies in focus.
Read
Commented by Fabian Lorenz on August 8th, 2024 | 07:00 CEST
Siemens Energy tops, Evotec shocks, and what is causing the dynaCERT share to explode?
The Evotec share lost more than 35% yesterday. The share was already trading at a multi-year low before this drop. Investors were particularly shocked by the adjustment to the EBITDA forecast. Additionally, the biotech company indicated that it plans to downsize. This year, Siemens Energy has shown how quickly a difficult situation can be resolved. On the verge of bankruptcy at the end of 2023, it is back on track, although not thanks to renewable energies. In contrast, dynaCERT has yet to see its share price explode. A former Daimler manager will take the helm in the coming days and is expected to secure orders in Europe. Additionally, dynaCERT investors are waiting for VERRA certification.
Read
Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST
In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac
The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.
Read
Commented by Fabian Lorenz on August 1st, 2024 | 06:30 CEST
Evotec slashed, Bayer sued, and Cardiol Therapeutics share praised
Anyone speculating on a quick rebound for Evotec will be disappointed. At present, one can at most speak of a bottoming out. It is fitting that a renowned analyst has slashed his price target for the German biotech share. Or is it only half as bad? Analysts see massive upside potential for the shares of Cardiol Therapeutics. The share price has more than doubled in the current year and is currently consolidating. There is an exciting entry opportunity now that positive study results have fizzled out on the stock market. Bayer, on the other hand, simply cannot get out of the world's courtrooms. In the US, a new lawsuit has been filed against the Leverkusen-based company; in another case, a multi-million dollar payment must be made.
Read
Commented by Stefan Feulner on July 30th, 2024 | 06:30 CEST
Viking Therapeutics, Vidac Pharma, Merck KGaA - In the footsteps of Novo Nordisk
Drugs for the treatment of diabetes and obesity have helped the pharmaceuticals manufacturer Novo Nordisk to become the most valuable listed company in Europe. But the competition is not sleeping. Many promising biotechs are already presenting new preparations that could overtake the Danes in the long term. Young companies with the chance of the next blockbuster also have great potential in other areas, such as cancer research.
Read
Commented by André Will-Laudien on July 25th, 2024 | 08:20 CEST
BioNTech, CureVac, Bayer, Cardiol Therapeutics, and Evotec: Tripled and still in turbo mode?
On the stock market, separating the wheat from the chaff is essential, especially in the biotech sector. This task becomes challenging when ongoing studies conclude, and their results must be interpreted. The market does not always react correctly to announcements, as evidenced by this year's acquisition of MorphoSys. While the stock market rejected the supposedly poor results, Novartis built up the first favourable positions, ultimately acquiring the Munich-based company for EUR 2.7 billion. From a low of around EUR 12, the acquisition price was a high EUR 68, making it a 500% deal. But opportunities are always lurking. Here is a selection of promising candidates.
Read
Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST
BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions
Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.
Read
Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST
70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!
Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?
Read
Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST
BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave
The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.
Read